Is Medicamen Organ. overvalued or undervalued?

As of 18 November 2025, the valuation grade for Medicamen Organ. has moved from attractive to fair. The company is currently fairly valued, with a PE ratio of 10.32, an EV to EBITDA of 8.33, and a ROCE of 11.09%. In comparison to its peers, Sun Pharma. is considered expensive with a PE ratio of 36.56, while Cipla is attractive with a PE ratio of 22.49.
Despite its fair valuation, Medicamen Organ. has underperformed significantly, with a year-to-date return of -46.47% compared to a 9.58% return for the Sensex. This underperformance highlights the potential concerns surrounding the company's growth prospects relative to its peers in the pharmaceuticals and biotechnology sector.